Avidity Biosciences’ (RNA) Buy Rating Reiterated at Needham & Company LLC
Needham & Company LLC reiterated their buy rating on shares of Avidity Biosciences (NASDAQ:RNA – Free Report) in a report released on Monday,Benzinga reports. They currently have a $60.00 target price on the biotechnology company’s stock. A number of other analysts have also recently issued reports on the stock. Citigroup initiated coverage on shares of […]
